Drug Research
CDMOs to benefit from rising BTDs, orphan drugs and fast track status
CPhI Worldwide – the world’s largest pharma event taking place in Frankfurt (5th – 7th November 2019) – has released the fourth part of its...
Drug Research
Bioeq announces Coherus as marketing and distribution partner for its biosimilar to Lucentis in the U.S.
Zürich, Switzerland. Bioeq IP AG has announced that it signed a license and development agreement with Coherus BioSciences, Inc. , under which Coherus will exclusively...
Drug Research
Sygnature Discovery invests in high-throughput screening capability
Sygnature Discovery has added in-house high-throughput screening (HTS) to its range of drug discovery services. This is backed up by its new Leadfinder compound library.
HTS...
Drug Research
BD Launches innovative two-step disposable autoinjector
Becton, Dickinson and Company (BD) has launched the BD Intevia 1 mL two-step disposable autoinjector, a robust platform device combining autoinjector and pre-fillable syringe in...
Drug Research
Shionogi and Hsiri to develop mycobacterial disease therapies
Japanese pharmaceutical firm Shionogi has signed a licence agreement with Hsiri Therapeutics for the discovery and development of therapies for non-tuberculous mycobacterial (NTM) diseases, as...
Drug Research
Adaptate Biotherapeutics formed to develop antibody-based therapies that modulate gamma delta T-cells
GammaDelta Therapeutics, a company focussed on harnessing the unique properties of gamma delta T-cells to develop transformational immunotherapies, announced the formation of a spin-out company:...
Drug Research
Insilico Medicine and ChemDiv form a strategic drug discovery service alliance
Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions. This collaboration combines...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.